Welcome to our dedicated page for Reshape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on Reshape Lifesciences stock.
Reshape Lifesciences Inc. (RSLS) is a medical device innovator focused on non-surgical solutions for weight management and metabolic health. This page provides investors and healthcare professionals with essential updates on corporate milestones, product developments, and clinical advancements.
Access timely announcements including regulatory approvals, strategic partnerships, and clinical trial outcomes. Our curated news feed helps stakeholders track the company’s progress in advancing alternatives to invasive obesity treatments and diabetes management technologies.
Key coverage areas include product innovation updates, financial disclosures, and market expansion initiatives. Bookmark this page for structured access to RSLS’s evolving role in the medical device sector, with neutral reporting suitable for both casual observers and professional analysts.
ReShape Lifesciences (Nasdaq: RSLS) announced updated guidelines from the ASMBS and IFSO for metabolic and bariatric surgery, which now recommend surgery for individuals with a BMI of 35 or more, regardless of comorbidities. The Lap-Band® is highlighted as the only FDA-approved device for weight reduction in this category. The new guidelines may significantly increase the number of eligible patients, enhancing access to weight loss procedures, particularly for those with a BMI over 30 and related health issues. These changes are expected to positively impact demand for Lap-Band® procedures and potentially boost revenues.
ReShape Lifesciences (Nasdaq: RSLS) announced promising results for its Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system, detailed in the journal Frontiers in NeuroScience. The study showed that DBSN™ effectively improved glycemic control in type 2 diabetic rat and swine models by blocking and stimulating vagus nerve signals. The therapy may reduce insulin resistance while increasing insulin release, positioning it as a novel, adjustable treatment for type 2 diabetes. This research was supported by NIH Small Business Innovation Research grants, confirming its potential impact on diabetes management.
ReShape Lifesciences (Nasdaq: RSLS) announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) has issued a new Consensus Statement on the management of Lap-Band® patients. This consensus, developed by 39 expert surgeons, includes 34 statements focused on aftercare practices and the efficacy of Lap-Band® as a weight loss solution. The report emphasizes the importance of behavioral health and nutrition in post-surgery care, aligning with ReShape's reshapecare™ program designed to support patients through virtual health coaching.
ReShape Lifesciences (Nasdaq: RSLS) has received a $300,000 Small Business Innovation Research (SBIR) grant to develop the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device for treating hypoglycemia. This device uses proprietary vagus nerve block technology in conjunction with a continuous glucose monitor. The funding will enable further development of the device, which aims to enhance glucose management and reduce hypoglycemia risks in diabetes patients. The technology is backed by 48 patents and has shown safety and efficacy in previous studies.
ReShape Lifesciences (Nasdaq: RSLS) announced participation in one-on-one meetings with institutional investors at the A.G.P. Virtual MedTech Conference on September 21, 2022. The company, focused on weight loss and metabolic health, offers various solutions, including the FDA-approved Lap-Band® Program and the ReShape Vest™ System. For more information, interested investors can contact their A.G.P. representative.
ReShape Lifesciences (Nasdaq: RSLS) has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Ansari brings over 30 years of experience in developing sales initiatives within the medical device industry, having previously held key roles at Enteromedics, Johnson & Johnson, and Medtronic. His leadership is expected to enhance sales growth for the Lap-Band® and strengthen ReShape's market presence globally. The Lap-Band® has successfully helped over one million patients achieve weight loss over the past two decades.
ReShape Lifesciences (RSLS) reported a 19% sequential revenue increase for Q2 2022, reaching $2.9 million, following decreased COVID-19 restrictions. The company secured FDA clearance for the GIBI HD calibration tube and appointed new CEO Paul F. Hickey, enhancing its leadership. Financially, RSLS experienced a decline in gross profit to $1.9 million, with adjusted EBITDA losses widening to $7.8 million. Expenses surged due to a robust DTC marketing campaign, though cash reserves of $11.5 million strengthen its position into 2023. The outlook remains cautiously optimistic as sales momentum builds.
ReShape Lifesciences (Nasdaq: RSLS) will report its Q2 2022 financial results on August 15, 2022, after-market. The company specializes in weight loss and metabolic health solutions. A conference call will be held on the same day at 4:30 pm ET, with access through their website. ReShape offers products like the FDA-approved Lap-Band Program and the investigational ReShape Vest System. Their services include reshapecare, a virtual weight-management program, and the ReShape Marketplace, an online wellness product collection.
ReShape Lifesciences (Nasdaq: RSLS) has received FDA 510(k) clearance for its Gastro Intestinal Balloon Indicator (GIBI HD™) calibration tube, designed for gastric and bariatric procedures. The GIBI HD™ will come in three sizes (32, 36, and 40 Fr) and aims to enhance surgical visibility and safety. U.S. commercial sales are set to commence in September 2022. The company plans to showcase the product at the IFSO 2022 World Congress in Miami. This advancement is part of ReShape's broader strategy to innovate weight loss solutions.
ReShape Lifesciences (Nasdaq: RSLS) has appointed Paul F. Hickey as its new President and CEO, effective August 15, 2022. He replaces Bart Bandy, who has left the company. Hickey brings over 25 years of medical device commercialization experience, notably serving as SVP of Marketing and Reimbursement at EnteroMedics, the predecessor to ReShape. Under his leadership, the company aims to advance its weight loss solutions, including the Lap-Band Program and reshapecare Virtual Health Coaching. Dan W. Gladney, chair of the Board, will take on a more active role as Executive Chair to support Hickey.
FAQ
What is the current stock price of Reshape Lifesciences (RSLS)?
What is the market cap of Reshape Lifesciences (RSLS)?
